RecruitingPhase 3NCT06596772
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients with Moderate to Severe Rheumatoid Arthritis
Sponsor
mAbxience Research S.L.
Enrollment
458 participants
Start Date
Oct 3, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 \[proposed etanercept biosimilar\] to Enbrel® \[EU-sourced\] in rheumatoid arthritis
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria17
- Inclusion
- Documented history of RA diagnosis consistent with the 2010 ACR/EULAR classification criteria ≥6 months prior to randomization (but not exceeding 15 years prior to screening).
- Moderately to severe RA despite appropriate MTX at baseline therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive protein \> 5.0 mg/dL and positive rheumatoid factor and/or CCP at screening
- Stable dose MTX between 10 to 25 mg weekly during ≥12 weeks, since ≥8 weeks prior to randomization
- Stable dose of NSAID and /or other analgesics for at least 4 weeks prior to randomization, when used
- Stable dose ≤10 mg prednisone daily or equivalent for ≥4 weeks prior to randomization, when used
- Patients who are otherwise medically stable according to investigator\'s discretion
- Agree to use highly effective contraceptive methods up to 6 months after las dose Exclusion
- Previously treated with any biologic or targeted synthetic DMARD
- Previously treated with any monoclonal antibody for other condition than RA
- Hypersensitivity to any component of study drug and/or prefilled syringe components
- Arthritis with onset prior to age 16 years or current diagnosis of inflammatory joint disease other than RA
- Systemic manifestations of RA other that rheumatoid nodules or secondary Sjogren\'s syndrome
- Active infection or potentially relapsing infections that could have a severe outcome. Latent tuberculosis infection detected during screening should start an approved treatment regimen according to standard of care and rescreened
- Solid or hematologic malignancy within the past 5 years
- Pregnant and breastfeeding women
- Any medical condition in the opinion of the investigator that would be a risk for safety, cooperation in the study or interferes with the interpretation of the study results
Interventions
DRUGMB04 (proposed biosimilar to etanercept)
MB04 50 mg/week via subcutaneous injection
DRUGEnbrel (etanercept)
Enbrel 50 mg/week via subcutaneous injection
Locations(60)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06596772
Related Trials
Plant-Based Diet for Patients With Rheumatoid Arthritis
NCT072683262 locations
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
NCT072774911 location
A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
NCT072347731 location
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
NCT065996583 locations
Dysphagia in Rheumatoid Arthritis
NCT074017322 locations